Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 03, 2014

MYLAN PHARMACEUTICALS, INC. v. CELGENE CORPORATION

Track this case

Case Number:

2:14-cv-02094

Court:

New Jersey

Nature of Suit:

Anti-Trust

Judge:

Esther Salas

Firms

Companies

Government Agencies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 31, 2019

    Celgene To Pay $62M To End Antitrust Suit Over Cancer Drugs

    Pharmaceutical company Celgene Corp. has agreed to fork over $62 million to resolve claims that it has suppressed competition for the brand-name cancer drugs Thalomid and Revlimid by preventing lower-priced generic versions from entering the market.

8 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login